Gaudium IVF Listing: Shares List at 5.06% Premium

Gaudium IVF and Women Health Limited, one of India’s premium fertility and reproductive healthcare chains, has officially entered the Indian capital markets today. Listing its shares on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE), the company made a significant milestone of being the first pure-play fertility and IVF services provider to go publicly listed in India.
The initial public offering (IPO), which is valued at Rs. 165 crore, is aimed at financing the company's expansion by establishing new IVF centres across India using its hub and spoke model and clearing outstanding corporate debt. However, despite the cautious sentiment that brewed in the unlisted market over the week, the shares listed at a premium of 5.06% against their upper price band of Rs 79.
Gaudium IVF listing performance
On the morning of February 27, 2026, Gaudium IVF shares made a debut on the Indian stock market, reflecting the rapidly cooling grey market premium (GMP) trends witnessed in the last few days of the Gaudium IVF IPO window.
The stock was priced in a band of Rs. 75 to 79, and in its listing debut on NSE and BSE, it got listed at Rs. 83 at a premium of 5.06%. It had a positive listing by beating the grey market estimates of flat or discount listing. A few minutes after the listing, the stock was trading around 1.50% up from its opening price.
Gaudium IVF IPO journey
The process of the public issue for Gaudium IVF started with the window of subscription that ran from February 20 to February 24, 2026. The company offered its shares in a price band of Rs. 75 to Rs. 79 per share with a minimum lot size of 189 shares. The total issue size of Rs. 165 crore was a combination of a fresh issue of Rs. 90 crore and an Offer For Sale (OFS) issue of Rs. 75 crore.
The IPO saw a healthy overall subscription of 7.27 times. The IPO subscription drive was primarily driven by Non-Institutional Investors (NIIs), who bid 14.05 times above their quota. Retail Individual Investors (RIIs) also showed strong interest, with subscriptions of 7.60 times. Meanwhile, Qualified Institutional Buyers (QIBs) were much more conservative, only booking their reserved portion 1.62 times on the last day. Its GMP on the last day of subscription was Rs. 0.
Gaudium IVF entered the primary market on the back of an impressive financial turnaround. In FY25, the company reported a total income of Rs 70.96 crore, a massive increase from Rs 48.15 crore in FY24. More importantly, its Profit After Tax (PAT) has registered a near 85% YoY growth to reach ₹19.13 crore in FY25 with very lucrative EBITDA margins of approximately 40%.
Wrap up
The positive listing of Gaudium IVF and Women Health represents the growing diversification of the Indian healthcare sector on the stock exchanges, and the focus has shifted from the traditional multi-speciality chains of hospitals to highly specialised niche healthcare providers.
As Gaudium IVF embarks on its new journey as a publicly listed entity, its ability to successfully scale its proprietary GAAT platform, expand its clinics into Tier-2 cities and manage its pending contingent liabilities would be important in justifying its premium valuation and rewarding its long-term shareholders in the fast-growing fertility market in India.









